Intestinal transplantation (ITx) has emerged as a key, but under-utilized and under-studied, therapeutic option for patients suffering from intestinal failure. Specifically, while an estimated 40,000 patients could benefit from ITx, a mere 141 ITx transplants were performed in the United States in 2015; the country's lowest volume solid organ transplant. This low volume is due to poor patient and allograft survival after ITx when compared to other fields of solid organ transplantation as this transplant is associated with the transplantation of the largest immune cell and microbial load of any solid organ. Because there is a high risk of allograft enteropathy/ immunological graft loss, strong regimens of generalized immunosuppression are typically applied, which lead to high morbidity and mortality. The result is a catch-22: if ITx is performed, the risk of rejection is high, which leads to over-immunosuppression, which results in complications and high treatment costs, which dissuades ITx from being offered in the first place. To untangle this catch-22 and unleash the potential of ITx, this project will leverage the fact that we are the leading ITx center in the country and lay the groundwork for a targeted immunotherapy approach to prevent/ control allograft enteropathy with minimization of generalized immunosuppression. Preliminary data has revealed that both the adaptive and innate immune systems are key players in stable allograft function and allograft enteropathy and as such, this project's three specific aims will focus on both systems: 1. To determine the roles and mechanisms of proinflammatory Th17 and protective regulatory T cell (Treg) responses in human ITx recipients with stable allograft function versus enteropathy 2. To determine the roles and mechanisms of proinflammatory type 1 innate lymphoid cell (ILC1) and protective type 3 innate lymphoid cell (ILC3) responses in human ITx recipients with stable allograft function versus enteropathy 3. To elucidate the crosstalk between the master regulators NOD2 (antimicrobial sensor) and CD39 (purinergic signaling) and innate and adaptive immune responses in human ITx recipients with stable allograft function versus enteropathy These three aims will lay the foundation for improving outcomes and quality of life for several patient groups: (A) patients who are on home-based TPN regimens could be considered for ITx, ideally before complications worsen that jeopardize the outcomes of ITx; (B) new and past recipients of ITx could avoid the life threatening complications from generalized immunosuppression, which will be especially beneficial for children who receive ITx in their earliest years of life; and (C) patients suffering from IBD could benefit from new therapeutic insights as we hypothesize that IBD is influenced by similar factors that modulate ITx enteropathy.

Public Health Relevance

For over 99% of the 40,000 Americans who could benefit from a life-altering intestinal transplant (ITx), the procedure is not an option due to the high risk of immunological complications and costs. ITx, the most under- used and under-studied solid organ transplant in the country, is also the one associated with the transplantation of the largest immune cell and microbial load ? which drives a high likelihood of allograft rejection/immunological graft loss and therefore leads to strong regimens of generalized immunosuppression with toxic side effects. The proposed project seeks to unleash the potential of ITx by understanding risk factors associated with immunologic graft loss at the intersection of the innate and adaptive immune systems and thereby providing insight into future targeted immunotherapies for the prevention/treatment of allograft rejection, which will be a substantial contribution to public health in light of the rising numbers of people with intestinal failure.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Transplantation, Tolerance, and Tumor Immunology Study Section (TTT)
Program Officer
Odim, Jonah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
Schools of Medicine
United States
Zip Code
Hawksworth, Jason S; Desai, Chirag S; Khan, Khalid M et al. (2018) Visceral transplantation in patients with intestinal-failure associated liver disease: Evolving indications, graft selection, and outcomes. Am J Transplant 18:1312-1320
Feldbrügge, Linda; Jiang, Z Gordon; Csizmadia, Eva et al. (2018) Distinct roles of ecto-nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in liver regeneration and fibrosis. Purinergic Signal 14:37-46
Jiang, Z Gordon; Sandhu, Bynvant; Feldbrügge, Linda et al. (2018) Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 16:1170-1172
Zhong, Alexander H; Gordon Jiang, Z; Cummings, Richard D et al. (2017) Various N-glycoforms differentially upregulate E-NTPDase activity of the NTPDase3/CD39L3 ecto-enzymatic domain. Purinergic Signal 13:601-609
Stolzenberg, Ethan; Berry, Deborah; Yang, De et al. (2017) A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity. J Innate Immun 9:456-463
Zhang, Haohai; Chan, Leo Li-Ying; Rice, William et al. (2017) Novel high-throughput cell-based hybridoma screening methodology using the Celigo Image Cytometer. J Immunol Methods 447:23-30
De Giorgi, Marco; Enjyoji, Keiichi; Jiang, Gordon et al. (2017) Complete deletion of Cd39 is atheroprotective in apolipoprotein E-deficient mice. J Lipid Res 58:1292-1305
Longhi, Maria Serena; Moss, Alan; Jiang, Zhenghui Gordon et al. (2017) Purinergic signaling during intestinal inflammation. J Mol Med (Berl) 95:915-925
Feldbrügge, Linda; Moss, Alan C; Yee, Eric U et al. (2017) Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. J Crohns Colitis 11:1113-1123